Brown Brothers Harriman & Co
BEAM icon

Brown Brothers Harriman & Co’s Beam Therapeutics BEAM Stock Holding History

Brown Brothers Harriman & Co’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-909
Closed -$35K – 1505
2022
Q2 		$35K Sell
909
-280
-24% -$11.1K ﹤0.01% 760
2022
Q1 		$68K Sell
1,189
-5,670
-83% -$372K ﹤0.01% 708
2021
Q4 		$547K Buy
6,859
+4,650
+211% +$398K ﹤0.01% 324
2021
Q3 		$192K Buy
+2,209
New +$222K ﹤0.01% 462

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown Brothers Harriman & Co's BEAM Position: Q3 2022 in Review

Brown Brothers Harriman & Co sold out of Beam Therapeutics (BEAM) in Q3 2022, closing a stake of 909 shares — an estimated $35K sold.

Brown Brothers Harriman & Co first reported a position in BEAM in Q3 2021 and held it in 4 quarters. The position peaked at $547K in Q4 2021. 224 funds tracked by Wall St. Rank hold BEAM as of Q3 2022.

  • Brown Brothers Harriman & Co reported no remaining Beam Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 909 Beam Therapeutics shares in Q3 2022, an estimated $35K.
  • Brown Brothers Harriman & Co first reported a position in Beam Therapeutics in Q3 2021 and held it in 4 quarters.
  • Brown Brothers Harriman & Co's Beam Therapeutics position peaked at $547K in Q4 2021.
  • 224 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2022.

Based on Brown Brothers Harriman & Co's 13F filing for Q3 2022, filed 14 Nov 2022.